According to a recent LinkedIn post from KROMATID, the company is sponsoring a scientific session at the American Society for Gene & Cell Therapy Annual Meeting in Boston focused on assessing genomic integrity in CRISPR-modified CAR-NK cells. The session will feature Dr. Dean A. Lee of Nationwide Children’s Hospital discussing how a panel of genomic assays supported an IND for a CD33 CAR-NK therapy in AML.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights themes such as characterizing donor variability, tracking changes from ex vivo expansion and gene editing, and using orthogonal cytogenetic methods, including G-banding and KROMASURE, to generate actionable insight. It also points to the importance of aligning genomic integrity testing with development milestones and includes participation from KROMATID’s VP of Platform, Erin Cross, on the role of single-cell analysis.
For investors, the content suggests that KROMATID is positioning its genomic integrity and single-cell analysis capabilities as part of the quality infrastructure supporting advanced cell therapies. Such visibility at a major industry meeting could enhance the company’s profile among cell and gene therapy developers, potentially supporting future demand for its platforms and strengthening its role in the clinical translation of engineered cell products.